We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Fisher Strengthens its Reagent Portfolio Through Acquisition of BioImage
News

Fisher Strengthens its Reagent Portfolio Through Acquisition of BioImage

Fisher Strengthens its Reagent Portfolio Through Acquisition of BioImage
News

Fisher Strengthens its Reagent Portfolio Through Acquisition of BioImage

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Fisher Strengthens its Reagent Portfolio Through Acquisition of BioImage"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Fisher Biosciences has acquired BioImage to expand its offering in high content screening and analysis reagent technologies.

BioImage, which is based in Copenhagen, Denmark, complements Fisher Biosciences' existing Cellomics business. 

The Cellomics platform includes automated imaging instrumentation, BioApplication image analysis software, High Content Informatics software and HitKit® HCS Reagent kits.

The entire Cellomics product portfolio is fully integrated to improve the quality and productivity of high content cell-based assays. 

BioImage is a leader in the field of High Content Pathway analysis, providing the life-science market with products, services and licenses that are based on its Redistribution® technology.

Redistribution is a patented technology that monitors protein translocation within a cell and is the basis for many of today's high content assays.

"The addition of BioImage further enhances our portfolio of high content cell-based assays and reagents," said Ron Lowy, president and chief executive officer of Fisher Biosciences. 

"Adding BioImage's Redistribution IP, assays, cell-lines and services to our already strong offering of high content screening instrumentation, software, siRNA and assay reagent kits, provides a more complete range of options to customers and strengthens Fisher's leadership position in high content screening."

Fisher will continue operations in Copenhagen.

Advertisement